Medical Device News Magazine

The American Kratom Association Issues Consumer Guidelines for Purchasing Kratom Products

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

As the popularity of kratom products grows in America, the kratom marketplace has become increasingly complex for consumers to differentiate and understand. Along with this product type complexity, the risks of purchasing dangerously adulterated kratom products are increasing dramatically. New and existing kratom vendors are trying to increase market share or differentiate their products by pushing products making illegal therapeutic claims, or are offering super-concentrated products that pose potential safety threats to average kratom consumers.

The FDA’s role should be to help consumers understand the marketplace and remove bad actors from it. However, they have simply declared all kratom products unlawful and are therefore ignoring the reality that millions of Americans have and will continue to use kratom increasingly as they prefer the improved sense of well-being they experience compared to when they consume coffee or products like energy drinks.

“The FDA has extensive experience with economically motivated adulteration (EMA)[1] that constitutes a fraud on consumers across a broad array of regulated products,” explained Mac Haddow, Senior Fellow on Public Policy with the American Kratom Association. “What is happening in the kratom marketplace is, in the absence of any responsible regulation by the FDA to protect kratom consumers, unscrupulous vendors are deliberately misleading consumers with illegal therapeutic claims, and more recently, with super-concentrated kratom products that pose real safety risks to the public.”

The American Kratom Association (“AKA”) issued its inaugural “Consumer Guidelines for Kratom Use” today to help consumers better understand how to use kratom most effectively for themselves and particularly how to identify misbranded, adulterated, and dangerously concentrated kratom products; and issued an appeal to FDA Commissioner Robert M. Califf, entitled “FDA – DO YOUR ACTUAL JOB!”, for the FDA to take immediate steps to fulfill its statutory duty to properly regulate kratom to protect consumers.

“The Consumer Guidelines for Kratom Use will be updated regularly to alert consumers to new threats that emerge from EMA in the kratom marketplace,” Haddow announced. “The real threat to the health and safety of the kratom consumer is the lack of action by the FDA while they are hell-bent to pursue their failed attempts to classify kratom as a Schedule I substance and thereby ban access to kratom by American consumers. That is why we are calling on Commmissioner Califf to listen to our plea for the FDA – DO YOUR ACTUAL JOB! and order its implementation at the FDA.”

The AKA’s concern is focused on two areas: (1) the lack of prosecution by the FDA of the more than 80 kratom vendors who openly market kratom products with illegal therapeutic claims and who have been reported (with supporting evidence) by the AKA to the FDA; and (2) the increasing marketing of super-concentrated kratom products that do not provide adequate labeling for consumers on the serving sizes and contents of the product that are openly marketed without any FDA regulations.

Without responsible regulation of kratom by the FDA, the proliferation of product competition is encouraging the marketing of super-concentrated kratom products to maintain market share. The FDA’s failure to properly regulate kratom encourages this market behavior, allows clearly adulterated kratom products to be marketed without any action by the FDA, and the FDA stands by while clearly unsafe kratom products are marketed in the same space as safe and tested products. This FDA allows this wild west marketplace to flourish, leading to predictable consumer confusion, puts consumers at significant risk, and serves only to create a false narrative for the FDA to recreate its currently failed case to ban all kratom products.

“The AKA is calling for the FDA – Do Your Actual Job! to fulfill its statutory duty to responsibly regulate the kratom marketplace with standards consistent with other dietary and botanical supplements, and then we are launching our Consumer Guidelines for Kratom Use so consumers understand their responsibility to purchase and consume kratom products that protects their health and well-being,” Haddow concluded. “Consumers should not purchase any kratom product marketed by unscrupulous vendors who fail to properly manufacture or label their products.”

[1] https://www.fda.gov/food/compliance-enforcement-food/economically-motivated-adulteration-food-fraud

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”